Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Asset / Drug

Evaluation

Drug and asset intelligence for Evaluation with 8 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
8
Catalysts
0
Stage
Development stage unavailable

Recent signals(8)

ClinicalAugust 16, 2026

Evaluation of SMART-HAND Protocol for Hand Rehabilitation in Rheumatoid Arthritis Patients

The SMART-HAND protocol is currently undergoing a randomized controlled trial led by Istanbul University - Cerrahpasa, aimed at assessing its effectiveness in enhancing hand function and proprioception in patients with rheumatoid arthritis.

ClinicalAugust 6, 2026

Evaluation of [11C]ZTP-1 Tracer for Imaging PDE4B in Healthy Subjects

[11C]ZTP-1 is being tested as a new tracer for imaging PDE4B levels in the brain and body.

CompetitiveAugust 2, 2026

Evaluation of LumiraDx D-Dimer Assay for VTE Diagnosis

The study assesses the accuracy of the LumiraDx D-Dimer assay in diagnosing venous thromboembolism.

ClinicalJuly 7, 2026

Evaluation of 18F-AIPF-1026 PET/CT in MAO-A-Related Diseases

A clinical trial is underway to assess the utility of 18F-AIPF-1026 PET/CT for diagnosing lesions in MAO-A-related diseases.

CompetitiveJuly 7, 2026

Evaluation of Gamified Mobile App for Depression Shows Promise in Reducing Symptoms

A study is evaluating a gamified mobile app aimed at reducing symptoms of depression through attention bias modification training.

ClinicalJuly 6, 2026

Evaluation of LTBI Screening Methods in HIV Patients in Liberia

A study is underway to compare IGRA and TST for latent TB screening in HIV-positive individuals in Liberia.

ClinicalJuly 5, 2026

Evaluation of OPTIBIO Tool for Medication Reduction in Rheumatoid Arthritis

A clinical trial is assessing the OPTIBIO predictive tool to guide medication reduction in RA patients in remission.

RegulatoryJuly 4, 2026

Evaluation of RonovoTM Robotic Surgical Platform in Oncological Procedures

A prospective registry is assessing the safety and performance of the RonovoTM robotic platform in oncological surgeries.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts

No catalysts indexed for this entity yet.

Indications

Infectious Disease →
Rheumatoid Arthritis →

Therapeutic areas

Digital Therapeutics →
Hematology →
Imaging Biomarker →
Infectious Disease →
Mental Health →
Neurology →
Oncology →
Rheumatoid Arthritis →
Rheumatology →
Surgical Robotics →
Tuberculosis →
Venous Thromboembolism →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.